A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622

Trial Profile

A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622

Not stated
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Hypereosinophilic syndrome
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline Research & Development
  • Most Recent Events

    • 25 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top